Iterative Scopes, Inc. (Iterative Health)

Iterative Health is a healthcare technology and services company dedicated to accelerating clinical research and improving patient outcomes. The company's mission is to bring life-changing therapies to patients sooner by transforming care through expertise and proven results, leveraging artificial intelligence and deep clinical trial knowledge. Iterative Health is headquartered in Cambridge, Massachusetts, with additional offices in New York, New York.

The company's core offerings include building and operating a high-performing, multispecialty clinical research network that integrates research directly into clinical care. They provide operational support, expert staffing, proprietary AI technology, and training to empower research teams and study sponsors. Key products include AI-based tools like "SKOUT" for automated polyp detection in colorectal cancer screening, utilizing machine learning and computer vision to interpret endoscopic images. While initially focused on gastroenterology and hepatology, Iterative Health has expanded its market segments to include cardiology and obesity.

Iterative Health recently secured $77 million in a Series C funding round in May 2026, led by Intrepid Growth Partners and GV (Google Ventures), bringing its total funding to over $270 million and achieving a valuation of approximately $1.3 billion. This funding supports the expansion of its AI-powered clinical research network and entry into new therapeutic areas. Jonathan Ng, MBBS, serves as the Founder and CEO. The company operates a global network of over 100 research sites across four continents and partners with more than 40 pharmaceutical, biotech, medical device companies, and contract research organizations, aiming to accelerate trial activation and patient enrollment.